Signos
Signos is a Continuous Glucose & Metabolic company founded in 2018 and based in San Jose, United States. It has raised $57M in total funding, most recently a Series B in 2023.
Founded around 2018 by Sharam Fouladgar-Mercer (CEO), Signos pairs a continuous glucose monitor with an AI app that delivers personalized, real-time recommendations to drive sustained weight loss. The company received FDA clearance as the first over-the-counter CGM system designed for weight management. Signos raised a $20M Series B in October 2023 led by Cheyenne Ventures and GV (Google Ventures), with Dexcom Ventures and Samsung Next participating, and announced a further $20M round in May 2026 from GV, Dexcom, and Blue Cross Blue Shield of Alabama. Its platform integrates Dexcom's Stelo biosensor and is distributed through Dexcom's direct-to-consumer channel.
Signos holds the first FDA clearance for an over-the-counter CGM aimed specifically at weight management, a regulatory milestone for the metabolic-wellness category.
signos.com ↗·Continuous Glucose & Metabolic·
United States·private 
